Patents by Inventor Robert C. Ladner

Robert C. Ladner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120328517
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Application
    Filed: August 9, 2012
    Publication date: December 27, 2012
    Applicant: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Publication number: 20120322744
    Abstract: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods.
    Type: Application
    Filed: May 3, 2012
    Publication date: December 20, 2012
    Applicant: DYAX CORP.
    Inventors: Arthur C. Ley, Aaron K. Sato, Robert C. Ladner, Mark Stochl
  • Patent number: 8288322
    Abstract: A library containing a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and that collectively display at least a portion of the family, the displayed peptides, polypeptides or proteins being encoded by DNA sequences containing sequences encoding a heavy chain CDR region is described.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: October 16, 2012
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Patent number: 8283321
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: October 9, 2012
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Patent number: 8188045
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: May 29, 2012
    Assignee: Dyax Corp.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Publication number: 20120107231
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Application
    Filed: December 22, 2011
    Publication date: May 3, 2012
    Applicant: DYAX CORP.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Patent number: 8124586
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 28, 2012
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • Publication number: 20120027686
    Abstract: The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.
    Type: Application
    Filed: July 28, 2011
    Publication date: February 2, 2012
    Applicant: DYAX CORP.
    Inventors: Daniel J. Sexton, Andrew Nixon, Anthony Williams, Robert C. Ladner, Qi-Long Wu
  • Patent number: 8106168
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: January 31, 2012
    Assignee: Dyax Corp.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Publication number: 20120015881
    Abstract: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.
    Type: Application
    Filed: September 8, 2011
    Publication date: January 19, 2012
    Applicant: DYAX CORP.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams, Maria Grazia De Simoni, Luigi Bergamaschini
  • Patent number: 8034775
    Abstract: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 11, 2011
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • Patent number: 7993646
    Abstract: The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: August 9, 2011
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Andrew Nixon, Anthony Williams, Robert C. Ladner, Qi-Long Wu
  • Publication number: 20110172125
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Application
    Filed: April 24, 2009
    Publication date: July 14, 2011
    Applicant: DYAX CORP.
    Inventor: Robert C. Ladner
  • Publication number: 20110172140
    Abstract: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods.
    Type: Application
    Filed: May 26, 2009
    Publication date: July 14, 2011
    Applicant: Dyax Corp.
    Inventors: Arthur C. Ley, Aaron K. Sato, Robert C. Ladner, Mark Stochl
  • Publication number: 20110152193
    Abstract: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 23, 2011
    Applicant: DYAX CORP.
    Inventors: William Markland, Robert C. Ladner
  • Publication number: 20110136746
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Application
    Filed: October 16, 2009
    Publication date: June 9, 2011
    Applicant: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Publication number: 20110118147
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Application
    Filed: March 13, 2009
    Publication date: May 19, 2011
    Inventor: Robert C. Ladner
  • Publication number: 20110086801
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Application
    Filed: November 22, 2010
    Publication date: April 14, 2011
    Applicant: DYAX CORP.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • Publication number: 20110082054
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long. Libraries encoding antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Application
    Filed: September 14, 2010
    Publication date: April 7, 2011
    Applicant: DYAX CORP.
    Inventor: Robert C. Ladner
  • Patent number: 7919462
    Abstract: This invention features novel proteins that are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and are capable of inhibiting plasmin and nucleic acids encoding these proteins. The invention also features the use of such proteins in therapeutic, diagnostic, and clinical methods.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: April 5, 2011
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner